Clinical trial
Cervical Cerclage for Preventing Spontaneous Preterm Birth in Singleton Pregnancies Without Prior Spontaneous Preterm Birth and With Short Transvaginal Ultrasound Cervical Length: a Randomized Clinical Trial
Name
17D.164
Description
The aim of this study is to evaluate the efficacy of cervical cerclage in prevention of spontaneous preterm birth in singleton pregnancies with a short transvaginal cervical length (\<=25mm) and without prior spontaneous preterm birth
Trial arms
Trial start
2017-09-22
Estimated PCD
2024-02-20
Trial end
2024-02-20
Status
Completed
Phase
Early phase I
Treatment
Cervical cerclage
Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
Arms:
Cerclage
Vaginal progesterone
Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
Arms:
Cerclage, Control
Size
93
Primary endpoint
Preterm birth <35 weeks
At delivery
Eligibility criteria
Inclusion Criteria:
* 18 year old or older
* Singleton pregnancy
* No prior SPTB or second trimester losses between 160 and 366 weeks
* TVU CL ≤25mm between 180 and 236 weeks
Exclusion Criteria:
* Multiple pregnancy
* Prior SPTB or second trimester losses between 160 and 366 weeks
* Cerclage in situ
* Painful regular uterine contraction and/or preterm labor
* Rupture membranes
* Major fetal anomaly or aneuploidy
* Active vaginal bleeding
* Placenta previa and/or accreta
* Cervical dilation \>1.0 cm and/or visible membranes by pelvic exam
* Suspicion of chorioamnionitis
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized trial of cerclage versus no cerclage in singleton pregnancies without prior spontaneous preterm birth and with a short transvaginal ultrasound cervical length', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 93, 'type': 'ACTUAL'}}
Updated at
2024-04-19
1 organization
1 product
1 indication
Organization
Thomas Jefferson UniversityProduct
Vaginal ProgesteroneIndication
Preterm Birth